{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Participants with one or more occurrences of one or more adverse events up to 8 weeks after the end of treatment. Participants with more than one event were only counted once.","groups":[{"description":"Romiplostim administered to adult participants subcutaneously weekly at doses up to 30 µg/kg based on platelet counts. After Amendment 1 the maximum weekly dose was reduced to 15 µg/kg, and after Amendment 2 the maximum weekly dose was reduced to 10 µg/kg. However, participants enrolled prior to Amendment 2 who were receiving \\>10 µg/kg were permitted to remain on that higher dose, but could not increase their dose. In addition, if the participant's dose was decreased, it could not be increased to \\>10 µg/kg.","id":"OG000","title":"Romiplostim in Adults"},{"description":"Romiplostim administered to pediatric participants subcutaneously weekly at doses up to 10 µg/kg based on platelet counts.","id":"OG001","title":"Romiplostim in Pediatric Population"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set, composed of all participants who received at least one dose of romiplostim","reportingStatus":"POSTED","timeFrame":"Duration of treatment plus 8 weeks (up to 285 weeks)","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}